Arvaya Healthcare approves acquisition of Sushodha Institute for Rs. 15.49 Crore
DIVIDEND
◆ Monitor Closely
MEDIUM RISK
📅 Filed on BSE: 11 Jul 2026, 02:58 PM IST · BSE ID: 679e343f-71bd-4677-ab75-fa3ff1dd2e7f
View Original BSE Filing (PDF)
💡
In Simple Terms
Arvaya Healthcare is buying another company, Sushodha Institute, for over Rs. 15 crore, paying with its own new shares.
🤖 AI Summary
- Arvaya Healthcare to acquire 100% of Sushodha Institute for Rs. 15,48,74,160.
- Consideration to be paid via issuance of 38,71,854 equity shares at Rs. 40 each.
- Board approved shifting of Registered Office from Assam to Maharashtra.
- Acquisition subject to necessary statutory and regulatory approvals.
🔢 Key Numbers — exact figures from BSE filing, not rounded
Acquisition of 100% equity shares of M/s Sushodha Institute of Gastroenterology Private Limited
1,84,374 Equity Shares
Total Purchase Consideration
Rs. 15,48,74,160/-
Purchase Price Per Equity Share
Rs. 840/-
Fully paid-up equity shares to be issued
38,71,854
Face value of equity shares issued
Rs. 10/-
Issue price per equity share
Rs. 40/-
🏢 How This Affects the Company
The acquisition of Sushodha Institute of Gastroenterology Private Limited is expected to expand Arvaya Healthcare's presence and capabilities in the gastroenterology sector.
The acquisition involves a purchase consideration of Rs. 15,48,74,160, to be settled by issuing approximately 38.72 lakh equity shares, diluting existing shareholding. This will impact the company's equity structure and potentially its balance sheet.
The transaction is subject to regulatory approvals, introducing a risk of delays or non-completion. The share issuance dilutes existing shareholders and introduces integration risks associated with the acquired entity.
👥 What This Means For Shareholders
✅
Action Required
No immediate action is required from shareholders. Monitor future announcements regarding regulatory approvals.
👤
Who Is Affected
All shareholders are affected by the proposed issuance of up to 38,71,854 equity shares, which will dilute their proportionate ownership.
🔍
Management Signal
Management is pursuing strategic growth through acquisition and optimizing operational base by shifting Registered Office.
For information only. Not investment advice. ForgeUp is not SEBI-registered.
👁 Watch List — track these upcoming events
Updates on regulatory and statutory approvals for the acquisition.
Confirmation of the Registered Office shift from Assam to Maharashtra.
Details on integration plan for Sushodha Institute of Gastroenterology.
MEDIUM RISK
Acquisition dependent on regulatory approvals; share issuance causes dilution.
💡 Investor Takeaway
Arvaya Healthcare is acquiring Sushodha Institute for Rs. 15,48,74,160 via equity issuance and relocating its Registered Office, subject to approvals.
⚖️ Strengths & Concerns
✅ Positives
- Acquisition of 100% equity in Sushodha Institute of Gastroenterology Private Limited approved.
- Purchase consideration of Rs. 15,48,74,160 for the acquisition finalized.
⚠️ Concerns
- Purchase consideration to be discharged via equity issuance, leading to dilution.
- Acquisition is subject to obtaining necessary statutory and regulatory approvals.
❓ Frequently Asked Questions
What is the total purchase consideration for acquiring Sushodha Institute of Gastroenterology Private Limited?
The total purchase consideration for acquiring 100% of Sushodha Institute of Gastroenterology Private Limited is Rs. 15,48,74,160/-.
How will Arvaya Healthcare pay for the acquisition of Sushodha Institute?
The purchase consideration will be discharged by issuing up to 38,71,854 fully paid-up equity shares of Arvaya Healthcare at Rs. 40/- per share.
What is the number of equity shares of Sushodha Institute being acquired?
Arvaya Healthcare is acquiring 1,84,374 Equity Shares of Rs. 10/- each of Sushodha Institute of Gastroenterology Private Limited.
Questions based on this BSE filing only. For information purposes.